{"component": "definition", "props": {"groups": [{"samples": [{"hash": "38mnQYl5fAl", "uri": "https://www.legis.iowa.gov/docs/ACO/GNAC/iacpdf(4-2-03)/iac/657iac/65730/65730.pdf", "label": "www.legis.iowa.gov", "score": 8.3600273785, "published": false}, {"hash": "auGR3fOkpip", "uri": "https://www.legis.iowa.gov/docs/iac/agency/10-03-2012.657.pdf", "label": "www.legis.iowa.gov", "score": 8.1704312115, "published": false}, {"hash": "4k68nBV9XUF", "uri": "https://www.legis.iowa.gov/docs/iac/agency/09-21-2011.657.pdf", "label": "www.legis.iowa.gov", "score": 8.1704312115, "published": false}], "size": 10, "snippet": "or \u201ccommittee\u201d means an impairment program provider, which may be a peer review committee or a committee of a professional pharmaceutical association or society, which has contracted with the board to provide an impairment program for the assistance of impaired Iowa pharmacy professionals and technicians.", "snippet_links": [{"key": "program-provider", "type": "definition", "offset": [35, 51]}, {"key": "peer-review-committee", "type": "definition", "offset": [68, 89]}, {"key": "a-committee", "type": "clause", "offset": [93, 104]}, {"key": "a-professional", "type": "clause", "offset": [108, 122]}, {"key": "the-board", "type": "clause", "offset": [188, 197]}, {"key": "to-provide", "type": "definition", "offset": [198, 208]}, {"key": "the-assistance", "type": "clause", "offset": [235, 249]}], "hash": "fb2892f3f7a421dfd7c9503cdd1ef081", "id": 1}, {"samples": [{"hash": "iitOP3CHqIm", "uri": "https://images.kw.com/docs/0/7/4/074602/1272867758885_CAR_Buyer_protection_Plan_for_2010.pdf", "label": "Mortgage", "score": 7.0533880903, "published": false}, {"hash": "hhujzOnJ7cS", "uri": "https://www.car.org/-/media/CAR/Documents/Your-CAR/PDF/HAF/REAP-2019-Application-nonwritable.pdf?la=en&hash=197E57A0C9809762D317458EA4F08F66EDA0C5C2", "label": "www.car.org", "score": 6.3045859001, "published": false}, {"hash": "gkwar8syAAs", "uri": "https://www.car.org/-/media/CAR/Documents/Alterian---import/PDF/REAP-Application_2017.pdf?la=en&hash=1BECD85B2CFE769CC97D2DFC11E5B245E1D9B722", "label": "www.car.org", "score": 5.8254620123, "published": false}], "size": 6, "snippet": "means the HAF Program Committee.", "snippet_links": [], "hash": "57d69b217641a8cdde33a0e7774d5b14", "id": 2}, {"samples": [{"hash": "kcFH2XCSGXH", "uri": "/contracts/kcFH2XCSGXH#program-committee", "label": "Research Agreement (Enumeral Biomedical Holdings, Inc.)", "score": 25.8295687885, "published": true}, {"hash": "64C3QxrFyWx", "uri": "/contracts/64C3QxrFyWx#program-committee", "label": "Research Agreement (Enumeral Biomedical Holdings, Inc.)", "score": 25.5995893224, "published": true}, {"hash": "a6xNGQ4FKLR", "uri": "/contracts/a6xNGQ4FKLR#program-committee", "label": "Research Agreement (Enumeral Biomedical Holdings, Inc.)", "score": 25.5968514716, "published": true}], "size": 4, "snippet": "shall have the meaning set forth in Section 4C.", "snippet_links": [], "hash": "c992bae81459a33c6c675c16a421efec", "id": 3}, {"samples": [{"hash": "emeRKDrqikU", "uri": "/contracts/emeRKDrqikU#program-committee", "label": "Focused Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3uu1Ht3AeOi", "uri": "https://investor.regeneron.com/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.9650924025, "published": false}, {"hash": "bNv3NN3IRdM", "uri": "https://investor.regeneron.com/index.php/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.3312799452, "published": false}], "size": 4, "snippet": "or \"PC\" means the committee established pursuant to Section 2.5(b).", "snippet_links": [{"key": "committee-established", "type": "clause", "offset": [18, 39]}, {"key": "pursuant-to-section", "type": "clause", "offset": [40, 59]}], "hash": "5b42c316a6e3913e508982fcdcd6be81", "id": 4}, {"samples": [{"hash": "2UOAksHmWwE", "uri": "/contracts/2UOAksHmWwE#program-committee", "label": "Collaboration and License Agreement (Lexicon Pharmaceuticals, Inc.)", "score": 26.3388090349, "published": true}, {"hash": "fTaFB3LxOf2", "uri": "/contracts/fTaFB3LxOf2#program-committee", "label": "Collaboration and License Agreement (Lexicon Genetics Inc/Tx)", "score": 18.0, "published": true}, {"hash": "2eKwenDmqJu", "uri": "/contracts/2eKwenDmqJu#program-committee", "label": "Collaboration and License Agreement (Lexicon Genetics Inc/Tx)", "score": 18.0, "published": true}], "size": 3, "snippet": "means the Joint Management Committee or the Joint Scientific Committee.", "snippet_links": [{"key": "joint-management-committee", "type": "definition", "offset": [10, 36]}, {"key": "joint-scientific-committee", "type": "clause", "offset": [44, 70]}], "hash": "f9c2a8fd01a2a392f8750ebdebfd746d", "id": 5}, {"samples": [{"hash": "jOk1NMpdCx", "uri": "/contracts/jOk1NMpdCx#program-committee", "label": "Option and License Agreement (Scholar Rock Holding Corp)", "score": 29.3175906913, "published": true}, {"hash": "idJkMk4KX8m", "uri": "/contracts/idJkMk4KX8m#program-committee", "label": "Option and License Agreement (Scholar Rock Holding Corp)", "score": 29.2984257358, "published": true}], "size": 3, "snippet": "has the meaning set forth in Section 3.9.", "snippet_links": [{"key": "section-39", "type": "clause", "offset": [29, 40]}], "hash": "d5ad5dd2a070466e1c035f8162a97e5a", "id": 6}, {"samples": [{"hash": "l85sn0bOEmL", "uri": "/contracts/l85sn0bOEmL#program-committee", "label": "Trust Fund Grant Agreement", "score": 24.3552361396, "published": true}, {"hash": "bHtkWfhoRe8", "uri": "/contracts/bHtkWfhoRe8#program-committee", "label": "Global Environment Facility Trust Fund Grant Agreement", "score": 21.0, "published": true}], "size": 2, "snippet": "means the committee referred to in paragraph 1 (a) (ii) (B) of Schedule 6 to this Agreement;", "snippet_links": [{"key": "the-committee", "type": "clause", "offset": [6, 19]}, {"key": "paragraph-1", "type": "clause", "offset": [35, 46]}, {"key": "schedule-6", "type": "clause", "offset": [63, 73]}, {"key": "to-this-agreement", "type": "clause", "offset": [74, 91]}], "hash": "5bf554e541cd33fc7ea1d6aaf9a6f6f9", "id": 7}, {"samples": [{"hash": "dFzWzokzmPc", "uri": "/contracts/dFzWzokzmPc#program-committee", "label": "Merchant Services Agreement (Zale Corp)", "score": 21.9336071184, "published": true}], "size": 1, "snippet": "means the Program Committee consisting of representatives of both Bank and Zale established pursuant to Section 2.2(a) of this Agreement and having the responsibilities set forth in Section 2.4(a) of this Agreement.", "snippet_links": [{"key": "the-program", "type": "clause", "offset": [6, 17]}, {"key": "representatives-of", "type": "clause", "offset": [42, 60]}, {"key": "pursuant-to-section", "type": "clause", "offset": [92, 111]}, {"key": "this-agreement", "type": "clause", "offset": [122, 136]}, {"key": "the-responsibilities", "type": "clause", "offset": [148, 168]}], "hash": "c5e965a8cc75304342466b048b376b07", "id": 8}, {"samples": [{"hash": "cMXZ09cxAj1", "uri": "/contracts/cMXZ09cxAj1#program-committee", "label": "Risk Coverage Agreement", "score": 21.0, "published": true}], "size": 1, "snippet": "is a committee of the Board comprised of one representative from each Program Participant in the Program and an alternate who may vote and exercise all powers of the representative in the representative's absence. A committee for a particular Program is identified as \"Program Committee (Name of Program).\"", "snippet_links": [{"key": "committee-of-the-board", "type": "clause", "offset": [5, 27]}, {"key": "comprised-of", "type": "clause", "offset": [28, 40]}, {"key": "program-participant", "type": "definition", "offset": [70, 89]}, {"key": "the-program", "type": "clause", "offset": [93, 104]}, {"key": "and-exercise", "type": "clause", "offset": [135, 147]}, {"key": "powers-of-the-representative", "type": "clause", "offset": [152, 180]}, {"key": "name-of-program", "type": "clause", "offset": [288, 303]}], "hash": "e87c5087fef2649f3bf2e572bcccf935", "id": 9}, {"samples": [{"hash": "dEITJ98h7JK", "uri": "/contracts/dEITJ98h7JK#program-committee", "label": "Focused Collaboration Agreement", "score": 20.340862423, "published": false}], "size": 1, "snippet": "or \"PC\" means the committee established pursuant to Section 2.5(b). 1.47. \"Regeneron Retained Projects\" means all research projects undertaken by the Parties pursuant to the Multi-Project Collaboration Agreement other than the Procter & \u2587\u2587\u2587\u2587\u2587\u2587 Retained Projects, the Mutual Retained Projects, and the Joint Projects, including, by way of example, but not limitation, the specific projects identified in Attachment 2.2(c) as \"Regeneron Retained Projects\". 1.48. \"Regeneron Technology\" means any invention, Know-how or other information, whether tangible or intangible, whether or not patentable in the Field, and which: (a) is not Regeneron Excluded Technology, and (b) is conceived or reduced to practice by Regeneron or acquired or licensed by Regeneron from a Third Party with the right to sublicense, (i) before or during the Research Term; or (ii) after the Research Term, but during the term of a J-V, regarding a Development Compound or Marketed Compound. Regeneron Technology may include, without limitation, research methods and materials (including without limitation genetic materials, receptors, cell lines and transgenic animals) useful in performing research, Targets, Compounds, formulations, chemical synthesis and manufacturing processes, methods of diagnosis and methods of treatment. 1.49. \"Research Collaboration Plan\" means, on a Fiscal Year basis, the compilation of objectives, prioritization of Research Projects and work on new areas of research, Success Criteria and overall budget for work by the Parties during the Research Term, but not including development and/or marketing activities. 1.50. \"Research Compound\" means a Compound that has not yet met the Success Criteria. 12 <PAGE> 1.51. \"Research Project\" shall mean research conducted by the Parties for the purpose of identifying, optimizing, and testing a specific Target, Validated Target and/or Research Compound. 1.52. \"Research Project Plan\" shall mean, on a Fiscal Year basis, the compilation of activities, milestones, budget, and Success Criteria relating to a Research Project. 1.53. \"Research Term\" means the period of time beginning on the Effective Date and unless terminated earlier pursuant to 10.3, ending December 31, 2005. 1.54. \"Retained Projects\" means the Mutual Retained Projects, Procter & \u2587\u2587\u2587\u2587\u2587\u2587 Retained Projects, and Regeneron Retained Projects. 1.55. \"Royalty Term\" means the period from the first Net Sales in the first country to the final payment of royalties in the last country pursuant to Section 6.1. 1.56. \"Section\" means any section of this Agreement. 1.57. \"Securities Agreements\" mean the following agreements between the parties: the Registration Rights Agreement, the Securities Purchase Agreement and the Warrant Agreement, all dated May 13, 1997, as each may be amended, supplemented or modified from time to time and the Stock Purchase Agreement and Registration Rights Agreement both dated December 11, 1996, as each may be amended, supplemented or modified from time to time. 1.58. \"Success Criteria\" means the specific criteria set forth in a Research Project Plan and Research Collaboration Plan and approved by the OC that define the minimum technical and commercial requirements for a Research Compound to be designated a Development or Lead Compound. 1.59. \"Sumitomo Compound\" means any Compound which: (a) is claimed by a Regeneron Patent; (b) is owned by Regeneron prior to the Effective Date, or conceived and solely reduced to practice solely by Regeneron during the Research Term; and", "snippet_links": [{"key": "committee-established", "type": "clause", "offset": [18, 39]}, {"key": "pursuant-to-section", "type": "clause", "offset": [40, 59]}, {"key": "retained-projects", "type": "definition", "offset": [85, 102]}, {"key": "research-projects", "type": "clause", "offset": [114, 131]}, {"key": "by-the-parties", "type": "clause", "offset": [143, 157]}, {"key": "the-multi", "type": "clause", "offset": [170, 179]}, {"key": "collaboration-agreement", "type": "definition", "offset": [188, 211]}, {"key": "the-mutual", "type": "definition", "offset": [263, 273]}, {"key": "joint-projects", "type": "definition", "offset": [301, 315]}, {"key": "specific-projects", "type": "clause", "offset": [371, 388]}, {"key": "regeneron-technology", "type": "definition", "offset": [462, 482]}, {"key": "other-information", "type": "definition", "offset": [517, 534]}, {"key": "in-the-field", "type": "clause", "offset": [594, 606]}, {"key": "excluded-technology", "type": "definition", "offset": [640, 659]}, {"key": "to-practice", "type": "clause", "offset": [693, 704]}, {"key": "by-regeneron", "type": "clause", "offset": [705, 717]}, {"key": "a-third-party", "type": "clause", "offset": [760, 773]}, {"key": "right-to-sublicense", "type": "clause", "offset": [783, 802]}, {"key": "during-the-research-term", "type": "clause", "offset": [818, 842]}, {"key": "after-the-research-term", "type": "clause", "offset": [852, 875]}, {"key": "term-of", "type": "clause", "offset": [892, 899]}, {"key": "development-compound", "type": "definition", "offset": [919, 939]}, {"key": "marketed-compound", "type": "definition", "offset": [943, 960]}, {"key": "methods-and-materials", "type": "clause", "offset": [1025, 1046]}, {"key": "including-without-limitation", "type": "clause", "offset": [1048, 1076]}, {"key": "cell-lines", "type": "definition", "offset": [1107, 1117]}, {"key": "chemical-synthesis", "type": "definition", "offset": [1207, 1225]}, {"key": "manufacturing-processes", "type": "clause", "offset": [1230, 1253]}, {"key": "research-collaboration-plan", "type": "clause", "offset": [1309, 1336]}, {"key": "fiscal-year-basis", "type": "clause", "offset": [1350, 1367]}, {"key": "work-on", "type": "definition", "offset": [1440, 1447]}, {"key": "new-areas", "type": "definition", "offset": [1448, 1457]}, {"key": "success-criteria", "type": "clause", "offset": [1471, 1487]}, {"key": "marketing-activities", "type": "clause", "offset": [1594, 1614]}, {"key": "research-compound", "type": "definition", "offset": [1623, 1640]}, {"key": "for-the-purpose-of", "type": "definition", "offset": [1782, 1800]}, {"key": "validated-target", "type": "definition", "offset": [1857, 1873]}, {"key": "research-project-plan", "type": "definition", "offset": [1907, 1928]}, {"key": "of-activities", "type": "clause", "offset": [1982, 1995]}, {"key": "relating-to", "type": "definition", "offset": [2038, 2049]}, {"key": "period-of-time", "type": "clause", "offset": [2102, 2116]}, {"key": "beginning-on-the-effective-date", "type": "clause", "offset": [2117, 2148]}, {"key": "royalty-term", "type": "definition", "offset": [2361, 2373]}, {"key": "period-from", "type": "definition", "offset": [2385, 2396]}, {"key": "net-sales", "type": "clause", "offset": [2407, 2416]}, {"key": "payment-of-royalties", "type": "clause", "offset": [2451, 2471]}, {"key": "section-61", "type": "clause", "offset": [2504, 2515]}, {"key": "this-agreement", "type": "clause", "offset": [2554, 2568]}, {"key": "securities-agreements", "type": "definition", "offset": [2577, 2598]}, {"key": "agreements-between-the-parties", "type": "clause", "offset": [2619, 2649]}, {"key": "the-registration-rights-agreement", "type": "clause", "offset": [2651, 2684]}, {"key": "securities-purchase-agreement", "type": "definition", "offset": [2690, 2719]}, {"key": "the-warrant-agreement", "type": "clause", "offset": [2724, 2745]}, {"key": "from-time-to-time", "type": "clause", "offset": [2820, 2837]}, {"key": "purchase-agreement-and-registration-rights-agreement", "type": "clause", "offset": [2852, 2904]}, {"key": "specific-criteria", "type": "definition", "offset": [3038, 3055]}, {"key": "approved-by", "type": "definition", "offset": [3129, 3140]}, {"key": "technical-and", "type": "clause", "offset": [3172, 3185]}, {"key": "requirements-for", "type": "clause", "offset": [3197, 3213]}, {"key": "lead-compound", "type": "definition", "offset": [3268, 3281]}, {"key": "sumitomo-compound", "type": "definition", "offset": [3290, 3307]}, {"key": "owned-by", "type": "definition", "offset": [3380, 3388]}, {"key": "prior-to-the-effective-date", "type": "clause", "offset": [3399, 3426]}], "hash": "7e277f7e0037a0c81338d68e76f5e8ae", "id": 10}], "next_curs": "Cl4SWGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjoLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIacHJvZ3JhbS1jb21taXR0ZWUjMDAwMDAwMGEMogECZW4YACAA", "definition": {"size": 46, "title": "Program Committee", "snippet": "or \u201ccommittee\u201d means an impairment program provider, which may be a peer review committee or a committee of a professional pharmaceutical association or society, which has contracted with the board to provide an impairment program for the assistance of impaired Iowa pharmacy professionals and technicians.", "id": "program-committee", "examples": ["Registry Operator understands that the mitigation measures required by ICANN as a condition to activation of names in the DNS zone for the TLD may include, without limitation, mitigation measures such as those described in Section 3.2 of the New gTLD Name Collision Occurrence Management Plan approved by the ICANN Board New gTLD <strong>Program Committee</strong> (NGPC) on 7 October 2013 as found at &lt;\u2587\u2587\u2587\u2587://\u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587/en/groups/board/documents/resolutions-\u00ad\u2010 new-\u00ad\u2010gtld-\u00ad\u2010annex-\u00ad\u20101-\u00ad\u201007oct13-\u00ad\u2010en.pdf&gt;.", "Registry Operator understands that the mitigation measures required by ICANN as a condition to activation of names in the DNS zone for the TLD may include, without limitation, mitigation measures such as those described in Section 3.2 of the New gTLD Name Collision Occurrence Management Plan approved by the ICANN Board New gTLD <strong>Program Committee</strong> (NGPC) on 7 October 2013 as found at &lt;\u2587\u2587\u2587\u2587://\u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587/en/groups/board/documents/resolutions-new-gtld-annex-1-07oct13-en.pdf&gt;.", "Registry Operator understands that the mitigation measures required by ICANN as a condition to activation of names in the DNS zone for the TLD may include, without limitation, mitigation measures such as those described in Section 3.2 of the New gTLD Name Collision Occurrence Management Plan approved by the ICANN Board New gTLD <strong>Program Committee</strong> (NGPC) on 7 October 2013 as found at &lt;\u2587\u2587\u2587\u2587://\u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587/en/groups/board/documents/resolutions-\u00ad\u2010n ew-\u00ad\u2010gtld-\u00ad\u2010annex-\u00ad\u20101-\u00ad\u201007oct13-\u00ad\u2010en.pdf&gt;.", "Registry Operator understands that the mitigation measures required by ICANN as a condition to activation of names in the DNS zone for the TLD may include, without limitation, mitigation measures such as those described in Section 3.2 of the New gTLD Name Collision Occurrence Management Plan approved by the ICANN Board New gTLD <strong>Program Committee</strong> (NGPC) on 7 October 2013 as found at &lt;\u2587\u2587\u2587\u2587://\u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587/en/groups/board/documents/resolutions- new-gtld-annex-1-07oct13-en.pdf&gt;.", "The Professional shall advise the Owner and the Project <strong>Program Committee</strong> as to cost of the Project and time requirements for planning and construction.", "The Work <strong>Program Committee</strong>, serving as the Transportation Committee for CMAP, will also continue its current reporting relationship to the Policy Committee.", "Registry Operator understands that the mitigation measures required by ICANN as a condition to activation of names in the DNS zone for the TLD may include, without limitation, mitigation measures such as those described in Section 3.2 of the New gTLD Name Collision Occurrence Management Plan approved by the ICANN Board New gTLD <strong>Program Committee</strong> (NGPC) on 7 October 2013 as found at &lt;\u2587\u2587\u2587\u2587://\u2587\u2587\u2587.\u2587\u2587\u2587\u2587\u2587.\u2587\u2587\u2587/en/groups/board/documents/resolutions-n ew-gtld-annex-1-07oct13-en.pdf&gt;.", "The TIDSS <strong>Program Committee</strong> shall develop processes, procedures and recommendations for the annual determination of course offerings and the designation of originating and remote site district locations.", "The Parties agree to establish a Joint Training <strong>Program Committee</strong>, which shall include up to three (3) persons from the bargaining unit appointed by the Union, and up to three (3) representatives of the Employer.", "At the beginning of each academic year, the <strong>Program Committee</strong> may choose to invite to join the Committee other faculty members who do not teach in the program."], "related": [["development-committee", "Development Committee", "Development Committee"], ["opsi-advisory-committee", "OPSI Advisory Committee", "OPSI Advisory Committee"], ["advisory-committee", "Advisory Committee", "Advisory Committee"], ["steering-committee", "Steering Committee", "Steering Committee"], ["transition-committee", "Transition Committee", "Transition Committee"]], "related_snippets": [], "updated": "2025-07-06T21:56:50+00:00"}, "json": true, "cursor": ""}}